Auranofin__IKK kinase inhibitor THZ2
Product Name
Auranofin
Description
IKK kinase inhibitor
Purity
>98% (HPLC)
CAS No.
34031-32-8
Molecular Formula
C20H34AuO9PS
Molecular Weight
678.5
Storage Temperature
-20ºC
Shipping Temperature
Shipped Ambient
Product Type
Inhibitor
Solubility
Soluble in DMSO (5 mg/ml) or 100% ethanol (4 mg/ml)
Source
Synthetic
Appearance
White solid
SMILES
CCP(=AuSemail protected1C@@H(email protected(C@@H(email protected(O1)COC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C)(CC)CC
InChI
InChI=1S/C14H20O9S.C6H15P.Au/c1-6(15)19-5-10-11(20-7(2)16)12(21-8(3)17)13(14(24)23-10)22-9(4)18;1-4-7(5-2)6-3;/h10-14,24H,5H2,1-4H3;4-6H2,1-3H3;/q;;+1/p-1
InChIKey
AUJRCFUBUPVWSZ-UHFFFAOYSA-M
Safety Phrases
Classification:
Acute toxicity, Oral (Category 3), H301
Reproductive toxicity (Category 2), H361
Safety Phrases:
S22 – Do not breathe dust.
S24/25 – Avoid contact with skin and eyes.
S36/37/39 – Wear suitable protective clothing, gloves and eye/face protection.
Hazard statements:
H301 Toxic if swallowed.
H361 Suspected of damaging fertility or the unborn child.
Precautionary statements:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P281 Use personal protective equipment as required.
P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/ physician.
P308 + P313 IF exposed or concerned: Get medical advice/ attention.
P321 Specific treatment (see supplemental first aid instructions on this label).
P330 Rinse mouth.
P405 Store locked up.
P501 Dispose of contents/ container to an approved waste disposal plant.
Cite This Product
Auranofin (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-493)
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/1911582
Alternative Names
1-Thio-β-D-glucopyranosatotriethylphosphine gold-2,3,4,6-tetraacetate, 3,4,5-Triacetyloxy-6-(acetyloxymethyl) oxane-2-thiolate triethylphosphanium, SKF 39162
Research Areas
Cancer, Apoptosis, Cancer Growth Inhibitors, Cell Signaling, Tyrosine Kinase Inhibitors
PubChem ID
24199313
Scientific Background
Auranofin is derivative of gold and has been widely used as an anti-arthritic drug. It inhibits both leukocyte activation pathways at multiple sites and the release of inflammatory mediators from human macrophages, basophils, and pulmonary mast cells. Auranofin has been shown to inhibit human neutrophil 5-lipoxygenase, thioredoxin reductase (TrxR), IκB kinase (IKK).
References
1. Betts W.H., Hurst N.P., Murphy G.A., & Cleland L.G. (1990) Biochem. Pharm. 39(7). 1233–1237.
2. Rudkowski R., Ziegler J.B., Graham G.G., & Champion G.D. (1991) Biochem. Pharm. 41(12): 1921–1929.
IKK kinase inhibitor
Acute toxicity, Oral (Category 3), H301
Reproductive toxicity (Category 2), H361
Safety Phrases:
S22 – Do not breathe dust.
S24/25 – Avoid contact with skin and eyes.
S36/37/39 – Wear suitable protective clothing, gloves and eye/face protection.
Hazard statements:
H301 Toxic if swallowed.
H361 Suspected of damaging fertility or the unborn child.
Precautionary statements:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P281 Use personal protective equipment as required.
P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/ physician.
P308 + P313 IF exposed or concerned: Get medical advice/ attention.
P321 Specific treatment (see supplemental first aid instructions on this label).
P330 Rinse mouth.
P405 Store locked up.
P501 Dispose of contents/ container to an approved waste disposal plant.
2. Rudkowski R., Ziegler J.B., Graham G.G., & Champion G.D. (1991) Biochem. Pharm. 41(12): 1921–1929.